For the quarter ended March 2025, Illumina (ILMN) reported revenue of $1.04 billion, down 3.3% over the same period last year. EPS came in at $0.97, compared to $0.09 in the year-ago quarter.
The reported revenue represents a surprise of +0.25% over the Zacks Consensus Estimate of $1.04 billion. With the consensus EPS estimate being $0.96, the EPS surprise was +1.04%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Illumina performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Product revenue: $880 million compared to the $872.04 million average estimate based on three analysts. The reported number represents a change of +0.5% year over year.
- Revenues- Core Illumina- Service and other revenue: $161 million versus the three-analyst average estimate of $175.08 million. The reported number represents a year-over-year change of -6.9%.
- Revenues- Core Illumina- Total product revenue: $880 million versus the three-analyst average estimate of $869.69 million. The reported number represents a year-over-year change of -0.3%.
- Revenue- Service and other revenue: $161 million versus the three-analyst average estimate of $170.12 million. The reported number represents a year-over-year change of -19.5%.
- Revenue- Sequencing- Instruments: $109 million versus $108.51 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -0.9% change.
- Revenues- Core Illumina- Instruments: $112 million versus the two-analyst average estimate of $112.06 million. The reported number represents a year-over-year change of -1.8%.
- Revenue- Sequencing- Consumables: $696 million versus $679.85 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -0.3% change.
- Revenue- Microarrays- Instruments: $3 million versus $3.61 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -25% change.
- Revenue- Microarrays- Consumables: $72 million versus the two-analyst average estimate of $74.59 million. The reported number represents a year-over-year change of +1.4%.
- Revenue- Core Illumina: $1.04 billion versus the two-analyst average estimate of $1.03 billion. The reported number represents a year-over-year change of -1.4%.
- Revenues- Core Illumina- Consumables: $768 million versus $748.87 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -0.1% change.
View all Key Company Metrics for Illumina here>>>
Shares of Illumina have returned +0.1% over the past month versus the Zacks S&P 500 composite's +11.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Illumina, Inc. (ILMN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
